Addenda Capital Inc. Increases Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Addenda Capital Inc. increased its stake in Thermo Fisher Scientific Inc. by 9.8% in Q2, now owning 21,068 shares valued at $8.55 million.
• Research analysts have mixed ratings on TMO, with 16 buy ratings and a recent price target range between $480.00 and $590.00.
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, with an ex-dividend date of September 15th, representing an annual yield of 0.4%.

Addenda Capital Inc. grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,068 shares of the medical research company's stock after buying an additional 1,880 shares during the period. Addenda Capital Inc.'s holdings in Thermo Fisher Scientific were worth $8,550,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also bought and sold shares of TMO. Revolve Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Intergy Private Wealth LLC grew its position in shares of Thermo Fisher Scientific by 5.8% during the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after buying an additional 23 shares during the last quarter. Root Financial Partners LLC boosted its stake in Thermo Fisher Scientific by 5.0% in the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock valued at $252,000 after acquiring an additional 24 shares during the period. Rossmore Private Capital raised its position in shares of Thermo Fisher Scientific by 0.5% during the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock worth $2,315,000 after purchasing an additional 24 shares during the period. Finally, ARS Wealth Advisors Group LLC grew its stake in Thermo Fisher Scientific by 1.6% during the 1st quarter. ARS Wealth Advisors Group LLC now owns 1,563 shares of the medical research company's stock worth $778,000 after buying an additional 25 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on TMO shares. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research report on Friday, July 11th. HSBC reiterated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Robert W. Baird raised their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Finally, Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Sixteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $588.35.

Thermo Fisher Scientific Trading Up 1.1%

Thermo Fisher Scientific stock opened at $464.18 on Friday. The company has a 50 day moving average price of $476.70 and a 200 day moving average price of $447.57. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77. The firm has a market capitalization of $175.28 billion, a price-to-earnings ratio of 26.85, a P/E/G ratio of 2.52 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 400 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.